| GHS 分類 | This chemical does not meet GHS hazard criteria for 90.7% (794 of 875) of all reports.Not ClassifiedAggregated GHS information provided per 875 reports by companies from 16 notifications to the ECHA C&L Inventory. |
|---|
| 規制情報 | Chemical: Phosphoric acid, monopotassium saltPhosphoric acid, potassium salt (1:1) is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Phosphoric acid, potassium salt (1:1) are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)Phosphoric acid, potassium salt (1:?) is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Phosphoric acid, potassium salt (1:?) are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)Status: Active Update: 11-04-2023 https://echa.europa.eu/registration-dossier/-/registered-dossier/15471Potassium phosphate, monobasic: Does not have an individual approval but may be used under an appropriate group standard |
|---|
| その他の安全情報 | IMAP assessments - Phosphoric acid, monopotassium salt: Environment tier I assessment |
|---|
| 火災危険 | Not combustible. Gives off irritating or toxic fumes (or gases) in a fire. |
|---|
| 有害性の概要 | A skin, eye, and respiratory tract irritant[ICSC] Emergency treatment: Inorganic phosphatesInorganic phosphates can cause diarrhea, hyperphosphatemia, and hypocalcemia after ingestionAn adult died after receiving four sodium phosphate enemas within 24 hourshe had electrolyte abnormalities and died from cardiac arrest[HSDB] |
|---|
| FDA 要件 | The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl potassium phosphate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.Potassium phosphates (mono, di, and tribasic) are indirect food additives for use only as components of adhesives. |
|---|
| Special Reports | WHODiseases Caused by Phosphorus and Its Toxic CompoundsEarly Detection of Occupational Diseases pg 53-62 (1986). Review of diseases and health related effects resulting from exposure to phosphorus or phosphorus cmpd. |
|---|
| FIFRA 要件 | Residues of potassium phosphate are exempted from the requirement of a tolerance when used in accordance with good agricultural practice as inert (or occasionally active) ingredients in pesticide formulations applied to growing crops or to raw agricultural commodities after harvest. Use: buffer. Limit: none.Potassium dihydrogen phosphate is exempted from the requirement of a tolerance in or on all food commodities when applied as a fungicide in accordance with good agricultural practices. |
|---|
| Chemical Dangers | Decomposes on heating. This produces toxic gases. The solution in water is a weak acid. |
|---|
| Hazard Classes and Categories | Not Classified |
|---|
| Critical Temperature and Pressure | Critical temperature = -151 °C |
|---|
| 消火 | In case of fire in the surroundings, use appropriate extinguishing media. |
|---|
| 応急処置措置 | Fresh air, rest.Rinse skin with plenty of water or shower.First rinse with plenty of water for several minutes (remove contact lenses if easily possible), then refer for medical attention.Rinse mouth. Give one or two glasses of water to drink. |
|---|
| 安全保管 | Separated from strong bases. |
|---|
| 消火手順 | Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials.As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing. |
|---|
| 保管条件 | Store at 20 to 25 °C (68 to 77 °F)excursions permitted to 15 to 30 °C (59 to 86 °F).Store in tight container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.Potassium phosphates injection should be stored at controlled room temperature. /Potassium phosphates/ |
|---|
| 清掃方法 | Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labeled container for disposal. Wash spill site. |
|---|
| 処分方法 | SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air qualitypotential migration in soil or watereffects on animal and plant lifeand conformance with environmental and public health regulations. |
|---|
| 漏出処分 | Personal protection: particulate filter respirator adapted to the airborne concentration of the substance. Sweep spilled substance into covered containers. |
|---|
| Preventive Measures | As a general rule, when handling USP Reference standards avoid all contact and inhalation of dust, mist and or vapors associated with the material. Wash thoroughly after handling.This material is assumed to be combustible. As with all dry powders it is advisable to ground mechanical equipment in contact with dry material to dissipate the potential build up of static electricity./Wear/ chemically compatible gloves, safety glasses or goggles and protect exposed skin. |
|---|
| Eye Prevention | Wear safety goggles. |
|---|
| Inhalation Risk | A harmful concentration of airborne particles can be reached quickly when dispersed, especially if powdered. |
|---|
| Skin Prevention | Protective gloves. |
|---|
| 相互作用 | Potassium supplements should not be administered to patients receiving potassium-sparing drugs such as amiloride, spironolactone, and triamterene. /Potassium Supplements/Concurrent use with potassium and sodium phosphates combination or monobasic potassium phosphate may increase plasma concentrations of salicylates since salicylate excretion is decreased in acidified urineaddition of these phosphates to patients stabilized on a salicylate may lead to toxic salicylate concentrations.Concurrent use with foods or medicines containing phosphates will decrease iron absorption because of the formation of less soluble or insoluble complexesiron supplements should not be taken within 1 hour before or 2 hours after ingestion of phosphates. /Phosphates/Use of potassium phosphates injection in digitalized patients with severe or complete heart block is not recommended because of possible hyperkalemia. /Phosphates/For more Interactions (Complete) data for MONOPOTASSIUM DIHYDROGEN PHOSPHATE (8 total), please visit the HSDB record page. |
|---|
| 生態毒性値 | LC50Species: Capitella capitata (Polychaete worm)Conditions: staticConcentration: 2400 ug/L for 28 daysSpecies: Neanthes arenaceodentata (Polychaete worm)Concentration: 1900 ug/L for 28 daysSpecies: Neanthes grubei (Polychaete)Concentration: 920 ug/L for 28 daysSpecies: Stauronereis rudolphi (Polychaete)Concentration: 2100 ug/L for 28 daysFor more Ecotoxicity Values (Complete) data for MONOPOTASSIUM DIHYDROGEN PHOSPHATE (7 total), please visit the HSDB record page. |
|---|
| 暴露経路 | The substance can be absorbed into the body by ingestion. |
|---|
| 毒性の概要 | The CIR Expert Panel concluded that the following 31 ingredients are safe in the present practices of use and concentration in cosmetics as described in this safety assessment, when formulated to be non-irritating...Potassium Phosphate...Safe for use in cosmetics, with qualifications |
|---|
| Signs and Symptoms | Cough.Redness.Redness. Pain.Abdominal pain. Vomiting. Diarrhoea. Nausea. |
|---|
| Soil Adsorption/Mobility | Monopotassium dihydrogenphosphate sorption was measured on soil and peat with the following results: 440 ug/g (Sceptre soil4.5% organic matter49% clay)440 ug/g Melfort soil10% organic matter46% clay)375 ug/g (Saskatchewan peatcharacteristics not specified)(1). |
|---|
| Human Toxicity Excerpts | /HUMAN EXPOSURE STUDIES/ The bioavailability and clinical effects of potassium phosphate monobasic and potassium phosphate dibasic were tested in 16 parenterally fed low birth weight infants at standard (n=8) and high levels (n=8) of mineral intakes using a constant infusion of macronutrients and vitamin D in a crossover design of 2 four-day periods. With standard intakes of calcium (35 mg/kg/day) and phosphorus (30 mg/kg/day) there was no difference between the monobasic and dibasic regimens on balance data or plasma biochemical monitoring. With the use of the monobasic regimen, the mineral intakes were doubled without precipitation in the infusate. This led to increased apparent retention of both calcium and phosphorus compared with that for standard levels of mineral intake. The improvement in calcium-phosphorus balance was accompanied by more severe calciuria and by metabolic compensation for an increased acid load. In addition to the possibility of exceeding the buffering capacity of the infant, this relative acidosis could also be evidence of improved bone mineralization./HUMAN EXPOSURE STUDIES/ The effects of intravenous administration of potassium phosphate in the treatment of diabetic ketoacidosis were studied in nine children, ages 9 9/12 to 17 10/12 yr. During phosphate infusion (20--40 mEq/L of fluid), all children maintained normal serum concentrations of phosphorus. Transient hypocalcemia occurred in six and transient hypomagnesemia in five patients. One child developed carpopedal spasms refractory to intravenous infusion of calcium gluconate but responsive to intramuscular injection of magnesium sulfate. In three patients, serum levels of intact parathyroid hormone were low at the time of hypocalcemia, an observation that suggests transient hypoparathyroidism. This study indicates that the use of potassium phosphate as the sole source of potassium replacement might potentiate ketoacidosis-induced hypocalcemia through multiple mechanisms./SIGNS AND SYMPTOMS/ Adverse reactions involve the possibility of combined potassium and phosphorus intoxication from overdosage. The signs and symptoms of potassium intoxication include paresthesias of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities such as disappearance of P waves, spreading and slurring of the QRS complex with development of a biphasic curve and cardiac arrest. Phosphorus intoxication results in a reduction of serum calcium, and the symptoms are those of hypocalcemic tetany./SIGNS AND SYMPTOMS/ /In potassium poisoning/ respirations are initially accelerated but skeletal muscle weakness may advance to stage of paralysis. /Potassium salts/For more Human Toxicity Excerpts (Complete) data for MONOPOTASSIUM DIHYDROGEN PHOSPHATE (10 total), please visit the HSDB record page. |
|---|
| Non-Human Toxicity Excerpts | /LABORATORY ANIMALS: Acute Exposure/ Potassium ... phosphate cause severe ulceration in the GI tract at a level equivalent to 1000 mg K+ ion when given to monkeys in form of a pill./LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Monopotassium phosphate showed no maternal toxicity or teratogenic effects at dose levels up to 320 mg/kg bw in mice and 282 mg/kg bw in rats./LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ ... Monopotassium phosphate /was/ not teratogenic in the developing chicken embryo./GENOTOXICITY/ Monocalcium phosphate, monopotassium phosphate and monosodium phosphate were not mutagenic in an in vitro assay using Saccharomyces cerevisiae strain D4 and Salmonella typhimurium strains TA1535, TA1537 and TA1538 with and without the addition of mammalian metabolic activation preparation.For more Non-Human Toxicity Excerpts (Complete) data for MONOPOTASSIUM DIHYDROGEN PHOSPHATE (6 total), please visit the HSDB record page. |
|---|
| Populations at Special Risk | Potassium supplements are contraindicated in patients with severe renal impairment with oliguria, anuria, or azotemiauntreated chronic adrenocortical insufficiency (Addison's disease)the hyperkalemic form of familial periodic paralysis or other hyperkalemiasacute dehydrationheat crampsor extensive tissue breakdown such as severe burns. /Potassium Supplements/ |
|---|
| Probable Routes of Human Exposure | According to the 2006 TSCA Inventory Update Reporting data, the number of persons reasonably likely to be exposed in the industrial manufacturing, processing, and use of monopotassium dihydrogen phosphate is 1000 or greaterthe data may be greatly underestimated(1). |
|---|
| Antidote and Emergency Treatment | /SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B//SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B//SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B//SRP:/ Immediate first aid: Remove patient from contact with the material. Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Inorganic Bases/Alkaline Corrosives and Related Compounds/For more Antidote and Emergency Treatment (Complete) data for MONOPOTASSIUM DIHYDROGEN PHOSPHATE (7 total), please visit the HSDB record page. |
|---|
| RAIS Toxicity Values | 1PPRTV Current4 |
|---|
| TSCA 収載状態 | TSCA listed |
|---|
